文献速递糖尿病

Acmopatide治疗超重或肥胖1型糖尿病成人患者的2期研究

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity.
PubMed 文献 · Diabetes Care · 2026-10-28

该研究为一项为期16周的2期随机、双盲、安慰剂对照、多中心试验,纳入HbA1c 7.0%–10.0%、BMI≥27 kg/m²的1型糖尿病成人患者,共111例随机分组。Acmopatide治疗组HbA1c较基线降低−0.4%至−0.6%,体重较基线降低−3.3%至−6.7%,均优于安慰剂。研究期间未发生糖尿病酮症酸中毒或严重低血糖事件。

要点

  • Acmopatide 4.1 mg组HbA1c较安慰剂多降低−0.3%,达到HbA1c<7.0%的比例为55.6%
  • Acmopatide各组体重较基线降低−3.3%至−6.7%,安慰剂组为0.3%
  • 试验期间未报告DKA或严重低血糖事件,不良事件以胃肠道反应为主

核心结论

  • 在超重或肥胖的1型糖尿病成人患者中,acmopatide与血糖控制改善及具有临床意义的体重下降相关,且未发生DKA或严重低血糖事件

研究设计与样本

  • 2期、16周、随机、双盲、安慰剂对照、多中心研究
  • 纳入HbA1c 7.0%–10.0%且BMI≥27 kg/m²的1型糖尿病成人患者,按1:1:1:1随机分配至每日一次皮下注射acmopatide 1.8 mg、4.1 mg、6.6 mg或等容积安慰剂
  • 共111例随机分组:安慰剂组29例,acmopatide 1.8 mg组27例,4.1 mg组28例,6.6 mg组27例
  • 基线平均HbA1c为7.5%,平均BMI为34.3 kg/m²

主要发现

  • Acmopatide各组HbA1c最小二乘均值较基线变化为−0.4%至−0.6%,安慰剂组为−0.3%
  • Acmopatide 4.1 mg组与安慰剂的校正后HbA1c差异为−0.3%,P=0.020
  • HbA1c<7.0%达标率:acmopatide 4.1 mg组为55.6%,安慰剂组为33.3%
  • Acmopatide各组体重较基线降低−3.3%至−6.7%,安慰剂组为0.3%
  • Acmopatide 4.1 mg和6.6 mg组每日总胰岛素剂量较安慰剂多降低−3.4%至−14.9%

关键数值与推荐

  • 主要终点为第16周HbA1c较基线变化
  • 次要终点包括体重较基线变化百分比和胰岛素剂量较基线变化
  • Acmopatide 4.1 mg组HbA1c安慰剂校正差异为−0.3%,P=0.020
  • Acmopatide各组体重较基线变化均P<0.01

临床怎么用

  • Acmopatide可能为超重或肥胖的1型糖尿病成人患者提供改善血糖控制和减重的辅助治疗选择
  • 临床使用需关注胃肠道不良反应,但本研究中未见DKA或严重低血糖

局限性

  • 研究周期为16周,长期疗效和安全性尚不明确
  • 部分HbA1c结果仅达到名义显著性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of acmopatide, a signal-biased glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist, in adults with type 1 diabetes (T1D) and overweight/obesity. RESEARCH DESIGN AND METHODS: In this phase 2, 16-week, randomized, double-blind, placebo-controlled, multicenter study, adults with T1D (HbA1c 7.0-10.0%; BMI ≥27 kg/m2) were randomized 1:1:1:1 to once-daily subcutaneous acmopatide (1.8, 4.1, or 6.6 mg) or volume-matched placebo. The primary end point was change from baseline (CFB) in HbA1c (%) at week 16; secondary end points included percent CFB in body weight and insulin dose. RESULTS: Overall, 111 participants were randomized (placebo n = 29, acmopatide 1.8 mg n = 27, 4.1 mg n = 28, 6.6 mg n = 27). Mean (SD) baseline HbA1c was 7.5% (0.6), and mean BMI was 34.3 (5.6) kg/m2. Acmopatide improved HbA1c (least squares [LS] mean CFB -0.4 to -0.6% vs. -0.3% with placebo; nominally significant placebo-adjusted difference for 4.1 mg: -0.3% [90% CI -0.6 to -0.1]; P = 0.020). HbA1c <7.0% was achieved by 55.6% of participants receiving acmopatide 4.1 mg vs. 33.3% receiving placebo. Acmopatide-treated participants demonstrated reductions in body weight (LS mean CFB -3.3 to -6.7% vs. 0.3% with placebo; all P < 0.01), total daily insulin dose (-3.4 to -14.9% more than placebo for acmopatide 4.1 and 6.6 mg), and mean systolic blood pressure (-3.1 to -8.4 mmHg vs. -3.3 mmHg with placebo). Adverse events were primarily gastrointestinal. No diabetic ketoacidosis (DKA) or severe hypoglycemia events occurred. CONCLUSIONS: In adults with T1D and overweight/obesity, acmopatide was associated with improved glycemic control and clinically meaningful weight loss without DKA or severe hypoglycemia events.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Klein, Pettus, Sonnenberg, et al. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity. Diabetes Care. 2026. PMID: 42949535. doi:10.2337/dc26-1059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。